Cerity Partners LLC Gilead Sciences, Inc. Transaction History

Cerity Partners LLC

$44.7 Billion
Q3 2024

A detailed history of Cerity Partners LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cerity Partners LLC holds 253,872 shares of GILD stock, worth $23.2 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

253,872

Previous 204,268 24.28%

Holding current value

$23.2 Million

Previous $14 Million 51.84%

% of portfolio

0.05%

Previous 0.04%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$66.59 - $83.99 $3.3 Million - $4.17 Million	49,604 Added 24.28%	253,872 $21.3 Million
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $1.82 Million - $2.1 Million	28,785 Added 16.4%	204,268 $14 Million
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $2.06 Million - $2.51 Million	28,743 Added 19.59%	175,483 $12.9 Million
Q4 2023 Jan 26, 2024	BUY	$73.27 - $83.09 $5.44 Million - $6.17 Million	74,249 Added 102.43%	146,740 $11.9 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $4.71 Million - $5.14 Million	-63,723 Reduced 46.78%	72,491 $5.43 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $2.42 Million - $2.76 Million	31,841 Added 30.51%	136,214 $10.5 Million
Q1 2023 May 11, 2023	SELL	$77.31 - $88.08 $147,739 - $168,320	-1,911 Reduced 1.8%	104,373 $8.66 Million
Q4 2022 Feb 15, 2023	BUY	$62.32 - $89.47 $886,003 - $1.27 Million	14,217 Added 15.44%	106,284 $9.12 Million
Q3 2022 Nov 10, 2022	BUY	$59.54 - $68.01 $141,705 - $161,863	2,380 Added 2.65%	92,067 $5.68 Million
Q2 2022 Aug 10, 2022	BUY	$57.72 - $65.01 $1.18 Million - $1.33 Million	20,391 Added 29.43%	89,687 $5.54 Million
Q1 2022 Apr 25, 2022	SELL	$57.92 - $72.58 $282,360 - $353,827	-4,875 Reduced 6.57%	69,296 $4.12 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $645,685 - $732,865	9,952 Added 15.5%	74,171 $5.39 Million
Q3 2021 Oct 25, 2021	SELL	$67.69 - $73.03 $155,213 - $167,457	-2,293 Reduced 3.45%	64,219 $4.49 Million
Q2 2021 Aug 11, 2021	SELL	$63.47 - $69.35 $818,953 - $894,823	-12,903 Reduced 16.25%	66,512 $4.58 Million
Q1 2021 Aug 11, 2021	SELL	$60.0 - $68.46 $14,040 - $16,019	-234 Reduced 0.29%	79,415 $5.13 Million
Q1 2021 May 12, 2021	SELL	$60.0 - $68.46 $180 - $205	-3 Reduced -0.0%	79,649 $5.15 Million
Q4 2020 Feb 11, 2021	BUY	$56.65 - $64.55 $133,184 - $151,757	2,351 Added 3.04%	79,652 $4.64 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $2.3 Million - $2.9 Million	37,108 Added 92.32%	77,301 $4.89 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $245,015 - $284,508	3,387 Added 9.2%	40,193 $3.09 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $310,456 - $397,650	-4,957 Reduced 11.87%	36,806 $2.75 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $1 Million - $1.1 Million	-16,302 Reduced 28.08%	41,763 $2.71 Million
Q3 2019 Oct 30, 2019	SELL	$62.51 - $69.0 $478,576 - $528,264	-7,656 Reduced 11.65%	58,065 $3.68 Million
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $1.72 Million - $1.93 Million	27,856 Added 73.57%	65,721 $4.44 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $657,440 - $736,505	-10,514 Reduced 21.73%	37,865 $2.46 Million
Q4 2018 Feb 06, 2019	BUY	$60.54 - $79.0 $122,472 - $159,817	2,023 Added 4.36%	48,379 $3.03 Million
Q3 2018 Nov 15, 2018	SELL	$71.28 - $78.92 $12,545 - $13,889	-176 Reduced 0.38%	46,356 $3.58 Million
Q2 2018 Aug 15, 2018	BUY	$64.88 - $75.68 $170,634 - $199,038	2,630 Added 5.99%	46,532 $3.3 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $100,300 - $122,277	-1,377 Reduced 3.04%	43,902 $3.31 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $304,948 - $357,966	-4,286 Reduced 8.65%	45,279 $3.24 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $3.57 Million - $4.24 Million	49,565	49,565 $4.02 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.

Account

Cerity Partners LLC Gilead Sciences, Inc. Transaction History